Literature DB >> 1715711

Small (CD14+/CD16+) monocytes and regular monocytes in human blood.

H W Ziegler-Heitbrock1, M Ströbel, G Fingerle, T Schlunck, A Pforte, M Blumenstein, J G Haas.   

Abstract

Compared to the obvious phenotypic and functional heterogeneity of tissue macrophages, little information is available on subsets of blood monocytes. We have employed two-color immunofluorescence and flow cytometry for the definition of regular and small monocytes, the latter characterized by the low-density expression of CD14 and the strong expression of the CD16 (Fcy-RIII) antigen. These cells comprise 15% of the blood monocytes and they appear to be similar in phenotype to the alveolar macrophage. The CD14+/CD16+ small monocytes can perform phagocytosis and they produce reactive oxygen, while their capacity for cytokine production is strongly reduced when compared to regular monocytes. At this point it is still unclear as to whether the CD14+/CD16+ small monocytes comprise a specific level of activation or differentiation or a distinct sublineage of human blood monocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715711     DOI: 10.1159/000163629

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  10 in total

1.  Phenotypic markers of alveolar macrophage maturation in pulmonary sarcoidosis.

Authors:  I Stríz; Y M Wang; H Teschler; C Sorg; U Costabel
Journal:  Lung       Date:  1993       Impact factor: 2.584

2.  Properties of human blood monocytes. I. CD91 expression and log orthogonal light scatter provide a robust method to identify monocytes that is more accurate than CD14 expression.

Authors:  Dorothy Hudig; Kenneth W Hunter; W John Diamond; Doug Redelman
Journal:  Cytometry B Clin Cytom       Date:  2013-10-08       Impact factor: 3.058

Review 3.  Standardizing immunophenotyping for the Human Immunology Project.

Authors:  Holden T Maecker; J Philip McCoy; Robert Nussenblatt
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

4.  CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis.

Authors:  A-L Feng; J-K Zhu; J-T Sun; M-X Yang; M R Neckenig; X-W Wang; Q-Q Shao; B-F Song; Q-F Yang; B-H Kong; X Qu
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

Review 5.  The role of monocytes and perivascular macrophages in HIV and SIV neuropathogenesis: information from non-human primate models.

Authors:  W-K Kim; X Avarez; K Williams
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

6.  Properties of human blood monocytes. II. Monocytes from healthy adults are highly heterogeneous within and among individuals.

Authors:  Dorothy Hudig; Kenneth W Hunter; W John Diamond; Doug Redelman
Journal:  Cytometry B Clin Cytom       Date:  2013-12-10       Impact factor: 3.058

7.  Optimization of protein solubilization for the analysis of the CD14 human monocyte membrane proteome using LC-MS/MS.

Authors:  Xiaoying Ye; Donald J Johann; Ramin M Hakami; Zhen Xiao; Zhaojing Meng; Robert G Ulrich; Haleem J Issaq; Timothy D Veenstra; Josip Blonder
Journal:  J Proteomics       Date:  2009-08-24       Impact factor: 4.044

Review 8.  The role of monocytosis and neutrophilia in atherosclerosis.

Authors:  Dimitry A Chistiakov; Andrey V Grechko; Veronika A Myasoedova; Alexandra A Melnichenko; Alexander N Orekhov
Journal:  J Cell Mol Med       Date:  2018-01-24       Impact factor: 5.310

9.  Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis.

Authors:  Holger Poehlmann; Joerg C Schefold; Heidrun Zuckermann-Becker; Hans-Dieter Volk; Christian Meisel
Journal:  Crit Care       Date:  2009-07-15       Impact factor: 9.097

10.  CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation.

Authors:  Alena Sekerkova; Eva Krepsova; Eva Brabcova; Janka Slatinska; Ondrej Viklicky; Vera Lanska; Ilja Striz
Journal:  BMC Immunol       Date:  2014-02-06       Impact factor: 3.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.